Characteristics of Hepatitis B Co-infection and Disease Evolution in HIV-Positive Paediatric Patients in Romania

Overview

Journal Balkan Med J

Publisher Galenos Publishing House

Specialty General Medicine

Date 2014 Sep 11

PMID 25207116

Authors

Manuela Arbune

Costinela Georgescu

Affiliations

Soon will be listed here.

Abstract

Background: Infection with hepatitis B virus (HBV) contributes to morbidity and mortality in people living with human immunodeficiency virus (HIV).

Aims: The aim of the present study is to assess the influence of HBV co-infection in clinical characteristics and disease evolution among nosocomial HIV infected youth in Romania.

Study Design: Retrospective study.

Methods: We assessed HBsAg in 179 young people with nosocomial paediatric HIV infection. Demographic data, ALAT level, CD4-count, HIV-RNA, antiretroviral therapy and clinical behaviour were all statistically compared in patients who were HIV mono-infected and HBV-co-infected.

Results: THE CHARACTERISTICS OF PATIENTS ARE AS FOLLOWS: sex ratio M/F: 55.3%, AIDS category 88%, median nadir CD4-count 126/mm(3). The prevalence of persistent HBsAg was 44.6%. The mortality rate was 11.1%, but no correlation with HBsAg was found. An average of three antiretroviral combinations is experienced by 97.7% of patients, including Lamivudine for over 5 years in 76% of cases and Tenofovir/Emtricitabine in 16.75% of patients. Patients under antiretroviral therapy achieved 53.07% sustained undetectable HIV-RNA and 40.78% restored immunity CD4-count >500/mm(3). ALAT enzyme was found to be high in 54.75% of patients.

Conclusion: During our research, we noticed that HBsAg was elevated in young people with HIV in Romania. Mortality rate was not statistically correlated to HBsAg. High ALAT levels are related with HBV, HDV co-infections, virological failure to antiretroviral treatment and the risk of death.

References

Audsley J, du Cros P, Goodman Z, McLean C, Mijch A, Lewin S . HIV replication is associated with increased severity of liver biopsy changes in HIV-HBV and HIV-HCV co-infection. J Med Virol. 2012; 84(7):993-1001. DOI: 10.1002/jmv.23236. View

. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41(RR-17):1-19. View

Matthews G, Avihingsanon A, Lewin S, Amin J, Rerknimitr R, Petcharapirat P . A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology. 2008; 48(4):1062-9. DOI: 10.1002/hep.22462. View

Dore G, Soriano V, Rockstroh J, Kupfer B, Tedaldi E, Peters L . Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS. 2010; 24(6):857-65. PMC: 2881334. DOI: 10.1097/QAD.0b013e328334bddb. View

Wang H, Han S . Management of hepatitis B in special patient populations. Clin Liver Dis. 2010; 14(3):505-20. DOI: 10.1016/j.cld.2010.05.002. View

Ruta S, Matusa R, Sultana C, Manolescu L, Kozinetz C, Kline M . High prevalence of hepatitis B virus markers in romanian adolescents with human immunodeficiency virus infection. J Int AIDS Soc. 2009; 7(1):68. PMC: 2740790. DOI: 10.1186/1758-2652-7-1-68. View

Apetrei C, Collin G, Letourneur F, Duca M, Saragosti S, Simon F . HIV type 1 subtype F sequences in Romanian children and adults. AIDS Res Hum Retroviruses. 1997; 13(4):363-5. DOI: 10.1089/aid.1997.13.363. View

Nikolopoulos G, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, Zavitsanos X . Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis. 2009; 48(12):1763-71. DOI: 10.1086/599110. View

Matthews G, Manzini P, Hu Z, Khabo P, Maja P, Matchaba G . Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS. 2011; 25(14):1727-35. DOI: 10.1097/QAD.0b013e328349bbf3. View

10.

Ofotokun I, Smithson S, Lu C, Easley K, Lennox J . Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy. Am J Med Sci. 2007; 334(5):334-41. PMC: 3075308. DOI: 10.1097/MAJ.0b013e31811ec780. View

11.

Soriano V, Grint D, Monforte A, Horban A, Leen C, Poveda E . Hepatitis delta in HIV-infected individuals in Europe. AIDS. 2011; 25(16):1987-92. DOI: 10.1097/QAD.0b013e32834babb3. View

12.

Ingiliz P, Valantin M, Thibault V, Duvivier C, Dominguez S, Katlama C . Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. Antivir Ther. 2008; 13(7):895-900. View

13.

Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C . Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005; 19(6):593-601. DOI: 10.1097/01.aids.0000163936.99401.fe. View

14.

Pitigoi D, Rafila A, Pistol A, Arama V, Molagic V, Streinu-Cercel A . Trends in hepatitis B incidence in Romania, 1989-2005. Euro Surveill. 2008; 13(2). View

15.

Liaw Y, Brunetto M, Hadziyannis S . The natural history of chronic HBV infection and geographical differences. Antivir Ther. 2010; 15 Suppl 3:25-33. DOI: 10.3851/IMP1621. View